Format

Send to

Choose Destination
See comment in PubMed Commons below
Dialogues Clin Neurosci. 2014 Jun;16(2):171-83.

Patient-reported outcomes before and after treatment of major depressive disorder.

Author information

1
Vice Chairman for Education & Research and Consultant Psychiatrist, Cedars-Sinai Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, USA; Cedars-Sinai Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, USA; David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, California, USA.
2
Cedars-Sinai Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, USA.
3
Richmond University Medical Center and Freedom From Fear, Staten Island, New York, USA.
4
Department of Psychiatry, Emory University School of Medicine.

Abstract

in English, French, Spanish

Patient reported outcomes (PROs) of quality of life (QoL), functioning, and depressive symptom severity are important in assessing the burden of illness of major depressive disorder (MDD) and to evaluate the impact of treatment. We sought to provide a detailed analysis of PROs before and after treatment of MDD from the large Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. This analysis examines PROs before and after treatment in the second level of STAR*D. The complete data on QoL, functioning, and depressive symptom severity, were analyzed for each STAR*D level 2 treatment. PROs of QoL, functioning, and depressive symptom severity showed substantial impairments after failing a selective serotonin reuptake inhibitor trial using citalopram (level 1). The seven therapeutic options in level 2 had positive statistically (P values) and clinically (Cohen's standardized differences [Cohen's d]) significant impact on QoL, functioning, depressive symptom severity, and reduction in calculated burden of illness. There were no statistically significant differences between the interventions. However, a substantial proportion of patients still suffered from patient-reported QoL and functioning impairment after treatment, an effect that was more pronounced in nonremitters. PROs are crucial in understanding the impact of MDD and in examining the effects of treatment interventions, both in research and clinical settings.

KEYWORDS:

STAR*D; functioning; individual burden of illness; major depressive disorder; quality of life

PMID:
25152656
PMCID:
PMC4140511
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dialogues in Clinical Neuroscience Icon for PubMed Central
    Loading ...
    Support Center